et al.. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study.Abstract word count: 236 Text word count: 5856 ABSTRACT 1 HIV controllers are rare individuals who spontaneously control HIV-1 replication for 10 years or 2 more in the absence of antiretroviral treatment. HIV controllers (n=11) maintained potent HIV-3 specific CD4 responses in spite of very low antigenic load. Their central memory (CM) CD4+ T 4 cells were characterized by near normal numbers, preserved IL-2 secretion in response to HIV 5 antigens, and uniformly high expression of the survival receptor IL-7Rα. Controllers expressed 6 CCR7 at higher levels than uninfected controls, suggesting differences in TCM cell homing 7 patterns. Effector memory (EM) CD4+ T cell responses were polyfunctional in HIV controllers, 8 while IL-2 secretion was lost in viremic patients. Cytokine production was 3 times higher in 9 controllers than in HAART-treated patients with undetectable viral load, suggesting an 10 intrinsically more efficient response in the former group. The total CD4+ TEM cell pool 11 underwent immune activation in controllers, as indicated by increased HLA-DR expression, 12 decreased IL-7Rα expression, a bias toward IFN−γ production upon polyclonal stimulation, and 13 increased MIP−1β secretion associated with chronic CCR5 down-regulation. Thus, HIV 14 controllers showed a preserved CD4+ TCM cell compartment and signs of a potent functional 15 activation in the CD4+ TEM cell compartment. While controllers did not show the generalized 16 immune activation pattern associated with disease progression, they had signs of immune 17 activation restricted to the effector compartment. These findings suggest the induction of an 18 efficient, non-detrimental type of immune activation in patients who spontaneously control HIV.
INTRODUCTION
HIV controllers are rare individuals who spontaneously control HIV replication to undetectable 2 levels in the absence of therapy. Controllers account for less than 1% of seropositive individuals 3 (33) and can be distinguished from long-term non progressors (LTNP), who were defined on the 4 basis of persistently elevated CD4+ T cell counts. While LTNP have a significant risk of 5 progressing to disease even after 10 years or more of asymptomatic infection, the HIV controller 6 status is associated with a very low risk of progression (10, 11, 37) . Controllers have HIV DNA 7 loads significantly lower than those of LTNP, emphasizing the importance of limited viral 8 dissemination in maintaining a healthy status in the long term (33, 52) . Attenuated virus, 9 characterized by major genetic defects such as deletions in the nef gene, have been isolated in 10 a few cases of controlled HIV infection (15, 31) . However, evidence for viral attenuation remains 11 uncommon. Virologic analyses of 8 of the HIV controllers included in the present study showed 12 that replication competent HIV could be isolated in each case, and suggested a degree of 13 ongoing viral replication in vivo based on phylogenetic evidence (34). Full-length sequencing of 14 HIV isolates obtained from another cohort of controllers did not reveal inactivating deletions or 15 mutations in the viral genome (7) . In addition, viral fitness of HIV clones obtained from these 16 isolates remained in the normal range (7) . Based on theses studies, HIV controllers appear 17 infected with fully replication competent virus in the vast majority of cases. Thus, host factors, 18 genetic or immunologic in nature, most frequently account for HIV control. 19 20 While the role of CD8+ T cells in clearing HIV-infected cells is clearly established (1, 3, 5, 21 6, 42, 43, 51) , several factors also point to the contribution of CD4+ T cells in HIV control. A 22 hallmark of non-progressive HIV infection is the presence of CD4+ T cells that proliferate in 23 response to HIV antigens, while this response is weak or absent in viremic patients (41, 50, 58) . 24 Evidence from murine models suggest that CD4+ T cells are needed to sustain an efficient CD8 25 antiviral responses in the long term (13, 39) . In rhesus macaques, attenuated simian 26 Hal-Pasteur author manuscript pasteur-00193768, version 1 immunodeficiency virus (SIV) infection induces a particularly high frequency of virus-specific 1 CD4+ T cells that have direct effector function (20) . Seronegative individuals who have been 2 repeatedly exposed to HIV also show signs of efficient CD4+ T cell proliferative responses to 3 HIV antigens (2). However, the causative link between strong CD4+ T cell responses and HIV 4 control is still under debate (38, 47) . Strong CD4+ T cell proliferative responses in treated 5 patients do not always predict a better virological outcome upon structured treatment interruption 6 (28), a possible reason being the rapid and preferential infection of HIV-specific CD4+ T cells in 7 the presence of replicating virus (18) . Most patients with progressive HIV disease still maintain 8 significant numbers of cytokine-producing CD4+ T cells when stimulated with HIV antigens (48). 9 The quality rather than the quantity of HIV-specific CD4+ T cells distinguishes slowly progressive 10 infection. It is associated with a particular cytokine-secretion profile, dominated by CD4+ T cells 11 that produce IL-2, either exclusively or in conjunction with IFN−γ. In contrast, high viremia is 12 associated with the loss of IL-2 secretion and a predominant IFN−γ response (8, 14, 19, 24, 25, 13 56, 60). 14 
15
A specific subset of memory CD4+ T cells is thought to be responsible for the long term 16 maintenance of immune memory. These cells, termed central memory (CM) CD4+ T cells, are 17 endowed with a self-renewal capacity which is thought to depend on autocrine IL-2 secretion 18 (30, 35) . In addition, CD4+ TCM cells express homing molecules such as CCR7 and CD62L that 19 allow their recirculation into secondary lymphoid organs, where recall responses are initiated. 20 Younes et al. (60) have proposed that persistent HIV antigenemia drives the differentiation of 21 CD4+ TCM cells into effector memory (EM) cells, that lose IL-2 secretion and thus self-renewal 22 capacity. Whether the loss of IL-2 secretion is a mere consequence of exposure to high 23 antigenemia or is the underlying cause for uncontrolled viral replication is not yet understood. In this context, it is important to characterize CD4 responses in HIV controllers, since 1 these responses are presumably optimal. Few studies have focused on CD4 responses in 2 patients with spontaneously undetectable viral load. We found that controllers had intrinsically 3 higher cytokine responses to HIV antigens than treated patients with undetectable viral load. HIV 4 controllers showed a unique CD4+ T cell activation pattern, characterized by the co-existence of 5 a preserved central memory compartment and an activated effector memory compartment. Such 6 activation status may account for both the persistence and potency of anti-HIV CD4 responses 7 in these rare patients. 
MATERIALS AND METHODS

10
Study design 11 HIV controllers were defined as HIV-infected patients who were seropositive for > 10 years, who 12 had received no antiretroviral treatment, and for whom >90% of the plasma viral load 13 measurements were <400 copies HIV RNA/ml. Controllers were identified among 1300 patients 14 followed at the Centre Hospitalo-Universitaire de Bicêtre (CHU Bicêtre, France) and 1500 15 patients of the ANRS SEROCO-HEMOCO cohort, with a frequency of 0.6 % in both cohorts. Ten
16
HIV controllers included in the present study have been described elsewhere (33) and two were 17 newly recruited (patients A9 and A10) (Table I ). In the course of the study, one patient (A8) 18 showed a viremic episode associated with bronchitis, but subsequently spontaneously controlled 19 his viremia to 100 copies /ml. The CCR5 ∆32 genotype was determined for all controller patients 20 by sequencing (I. Théodorou, INSERM U543).
22
Control groups included: (1) non-infected healthy blood donors from the Etablissement 23 Français du Sang (Paris, France); (2) viremic patients with a viral load >2,000 copies HIV 24 RNA/ml who had been infected with HIV for at least 6 months and did not receive antiretroviral 6 years and with <50 copies HIV RNA/ml. Patients from the last two groups were followed at the 1 CHU Bicêtre. Summaries of patients characteristics, CD4+ T cell counts and viral load data are 2 reported in Table II. The study was approved by Comité Consultatif de Protection des Personnes   3 dans la Recherche Biomédicale de l'Hôpital Bicêtre. All participants gave written informed 4 consent prior to blood sampling. 5 6 Intracellular cytokine staining (ICS) assays 7 Cryopreserved PBMC stored in liquid nitrogen were thawed and left to recover at 37 °C in 8 complete medium (RPMI 1640 supplemented with glutamine 2 mM, antibiotics and 10% human 9 AB serum) for 8-9 hours. HIV-specific stimulation was performed by adding baculovirus-derived 10 recombinant p24 Gag protein (Protein Sciences) at 5 µg/ml to 2 x 10 6 PBMC. Cells were 11 stimulated for 14 hours, with brefeldin A (5 µg/ml; Sigma) added after the first 2 hours of 12 stimulation. Polyclonal stimulation was performed by incubating 0.6 x10 6 PBMC in a 96-well 13 plate pre-coated with anti-CD3 antibody (0.6 µg/ml; clone UCHT1, Immunotech) in the presence 14 of 0.5 µg/ml soluble anti-CD28 antibody (clone CD28.2, Immunotech), with brefeldin added after 15 the first 2 hours. Following stimulation, cells were harvested from wells and stained for surface 16 antigens with the following combination of antibodies (all purchased from BD Biosciences unless 17 otherwise specified): CD3-PerCP, CD45RA-PE-Cy7, CCR7-APC (R&D Systems), and CD4-18 APC-Cy7. Cells were fixed and permeabilized using an Intraprep permeabilization kit (Beckman 19 Coulter) according to the manufacturer's instructions. Intracellular cytokine staining was detected 20 with IFN−γ-Carboxyfluorescein (clone 25723.11, R&D Systems) and IL-2-PE (clone MQ1-21 17H12). Fluorescence was measured on a 6-color flow cytometer (FacsCanto) using the 22 FACSDiva software (BD Biosciences). Data were analyzed with FACSDiva and FlowJo 8.1 23 (Tree Star).
24
For p24-stimulated cultures and unstimulated control cultures, a minimum of 750,000 25 lymphocyte−gated events were acquired. The percentage of cytokine-producing CD4+ T cells 26 7 was determined after subtracting the percentage of cytokine-positive events in unstimulated 1 controls. Responses that were below 0.01% cytokine-producing cells were considered negative. 2 None of the 10 HIV-seronegative donors tested showed a positive cytokine response upon p24 3 stimulation. 4 To detect chemokine MIP−1β (CCL4) production, PBMC were stimulated either with p24 5 Gag (5 µg/ml) or with the superantigen Staphylococcus Enterotoxin B (SEB, 1 µg/ml, Toxin 6 Technology). ICS was performed as described above, except that the IL-2 antibody was 7 replaced with a MIP−1β-PE antibody (clone D21-1351, BD Biosciences). Phenotyping was carried out on fresh PBMC samples. Blood (20-30ml) was collected in 11 heparinized tubes and PBMC separated by Ficoll-Paque (Pharmacia) density centrifugation. 12 Four-colour antibody staining was performed on 10 6 PBMC at 4 °C for 30min. CD4+ T cell 13 subsets were defined using antibodies CD45RA-FITC, CD4 PE-Cy7 (BD Biosciences) and Proliferation was assayed by [3H]-thymidine incorporation as described previously (32). Briefly, 2 PBMC at 10 5 cells per well were treated in quadruplicate with p24 Gag protein at 5 µg/ml. 3 Positive controls were stimulated with 5 µg/ml phytohemagglutinin and negative controls were 4 incubated with complete medium alone. On day 5, each well was pulsed with 1 µCi [3H]-5 thymidine (Amersham). Sixteen hours later, cells were harvested onto glass fiber filters, and 6 radioactivity was quantitated with a b-scintillation counter (Wallac, Perkin Elmer). The stimulation 7 index (SI) was computed as median [3H]-thymidine incorporation in stimulated cells/median 8 [3H]-thymidine incorporation in unstimulated cells. A positive response was defined as both an 9 SI >3 and a median count >3000 in the stimulated wells. 
Preserved central memory compartment with high CCR7 expression in HIV controllers
4 CD4+ T cell subsets were defined according to the expression of the CD45RA and CCR7 5 markers (Fig. 3A) . The percentage of naive CD4+ T cells (CD45RA+ CCR7+) was variable and 6 did not distinguish the different groups studied (Fig. 3B ). The percentage of CD4+ central 7 memory (CM) CD4+ T cells (CD45RA-CCR7+) was heterogenous in the controller group, but 8 did not differ significantly from that of non-infected controls (Fig. 3C ). In contrast, the CD4+ TCM Cytokine responses were evaluated in the different CD4+ T cell subsets using 6-color flow 3 cytometry. HIV-specific cytokine production by naive CD4+ T cells was below detection 4 threshold (not shown). Cytokine production was 6 to 10 times more abundant in CD4+ TEM than 5 TCM cells (compare Fig. 4A and B ). The percentage of TEM cells that produced IFN−γ only was 6 equivalent in the controller and viremic groups, while HIV controllers were characterized by the 7 presence of additional populations of TEM cells that produced IL-2 only, or both IL-2 and IFN−γ. 8 HIV-specific cytokine production was approximately 3 times lower in CD4+ TEM cells of HAART-9 treated patients compared to controllers (Table III) . IL-2 secretion by TEM cells remained 10 detectable in the HAART group, although the proportion of IL-2+ cells, including dual producers, 11 was slightly reduced as compared to the HIC group ( Fig. 4B , 37% versus 52 %, respectively).
12
HIV-specific cytokine responses were markedly different in the central memory 13 compartment. CD4+ TCM cells of HIV controllers maintained the capacity to produce cytokines 14 upon p24 Gag stimulation, with a predominant IL-2 secretion pattern ( Fig. 4A ). In contrast, these 15 responses were minimal in viremic and HAART-treated patients. Notably, the bulk of IL-2 16 secretion was not carried out by TCM cells but rather by TEM cells, the percentage of IL-2+ cells 17 being 4 times higher in TEM compartment (ratio TEM/TCM= 4.7 in the HIC group and = 4.2 in 18 the HAART group; Table III ). IL-2 production by HIV-specific CD4+ TCM cells is not 19 quantitatively the most important, but may nevertheless contribute to HIV control due to the long 20 half-life and self-renewing capacity of TCM cells. Thus, it was important to note that the TCM 21 response appeared qualitatively different in the HIV controller group.
23
Skewed polyclonal responses in HIV controllers
production upon stimulation with anti-CD3/anti-CD28 antibodies. CD4+ TCM cells responded to 1 polyclonal stimulation by a predominant IL-2 production, while CD4+ TEM cells produced a 2 mixed response, with both IL-2 and IFN−γ production (compare Fig. 4C and 4D ). The intensity of 3 polyclonal responses was of the same order of magnitude in TCM and TEM cells, indicating that 4 TCM cells were not inherently limited in their cytokine secretion capacity.
6
The intensity of total polyclonal responses did not differ markedly between the HIC, 7 HAART and uninfected groups (Table III) . In particular, CD4+ T cells from HIV controllers did not 8 appear endowed with an intrinsically high IL-2 secretion capacity that could have accounted for 9 the maintenance of HIV-specific TCM responses. Polyclonal responses were significantly 10 decreased in the viremic group, both in the TEM and the TCM compartment (Table III) . These 11 observations underscored a generalized defect of CD4+ T cell-dependent immunity in viremic 12 patients, as previously reported (54). Interestingly, the proportion of TEM cells producing IFN−γ 13 only upon polyclonal stimulation was significantly higher in HIV controllers than in uninfected 14 blood donors (p=0.01; Table III ). This finding suggested that global CD4+ T cell responses were 15 somehow altered in HIV controllers, even though these patients appeared healthy and 16 suppressed HIV replication efficiently. A similar phenomenon was observed for viremic and 17 HAART-treated patients, who showed an increased proportion of IFN−γ producers upon anti-18 CD3/CD28 stimulation as compared to uninfected donors (p<0.001 and p<0.05, respectively). 19 Thus, HIV infection primed the pool of CD4+ TEM cell for IFN−γ production in controllers as well 20 as in other patients groups. 23 The observation of a priming for IFN−γ production suggested that the CD4+ T cell compartment 24 may not be in a resting state in HIV controllers. We therefore assessed the expression of 25 13 activation markers at the surface of CD4+ T cells. Phenotyping studies were carried out for a 1 subset of HIV controllers (patients A1 to A8, n=8) and for patients from control groups (n=8 for 2 each group; Table II ). As expected, the expression of HLA-DR was increased in viremic patients, 3 both in the CD4+ TCM and TEM cell compartments (Fig. 5A ). HIV controllers showed an 4 intermediate pattern, with an increase of HLA-DR expression in CD4+ TEM cells, but no 5 significant changes in CD4+ TCM cells. The increase of HLA-DR expression in TEM cells was 6 heterogeneous, suggesting variable activation levels in the controller group. However, individual 7 variability was also observed in the viremic group, and median HLA-DR expression was 8 comparable between the two groups (12.3% vs 13.2% for HIC and VIR, respectively). The 9 percentage of CD25 expression was not increased in controllers or viremic patients (not shown). The alpha chain of the IL-7 receptor (CD127) is lost upon antigen exposure, and re-21 expressed in CD4+ memory T cells that survive in the long term (17). CD127 expression was 22 uniformly high in CD4+ TCM cells of controllers, while it was decreased in those of viremic and 23 HAART-treated patients (Fig. 5C ). Interestingly, CD127 showed a trend to decrease in CD4+ activation in this compartment. Thus, the phenotyping analysis showed signs of a preferential 1 activation of the TEM compartment in HIV controllers. Given that the level of T cell activation has 2 been described as a surrogate marker for HIV disease progression (21), it was striking to find 3 that, within the TEM compartment, levels of HLA-DR expression were as high in HIV controllers 4 as in progressors. the cells involved in the polyclonal response. We also evaluated MIP−1β responses in the CD8+ 10 T cell compartment, since CD8+ T cells are known to produce CCR5 ligands at high levels (57).
22
Activation of the effector memory compartment in HIV controllers
11
Upon polyclonal stimulation, CD8+ T cells from all patients groups produced MIP−1β at higher 12 levels than CD8+ T cells from uninfected donors (Fig. 6C, right panel) . Thus, HIV infection 13 primed the total T cell pool for increased MIP−1β production, a finding that may account for the 14 downregulation of CCR5. It was noteworthy that levels of HIV-specific CD4+ T cell responses were higher in HIV 24 controllers than in HAART-treated patients. The strength of CD4 responses has been proposed 25 to follow a bell-shaped curve, with a positive association between CD4 responses and viral load 1 in the low viral load range (29, 59) . HIV controllers were exposed to very low levels of HIV 2 antigens, given their particularly low level of viral DNA (median = 43 copies/ 10 6 PBMC; Table I) (Table   12 II), which is not unusually low, but is still associated with a degree of long-term immune damage. 13 On the other hand, HIV controllers may share genetic traits that promote the development of immunological memory in murine models indicate that T cells that have encountered their 24 cognate antigen and re-express CD127 will preferentially survive the encounter, while CD127-study, expression of CD127 on antigen-exposed CD4+ T cells is dependent on the presence of 1 IL-2 (17). Thus, the IL-2 secretion capacity of HIV-specific T cell in controllers may contribute to 2 the high CD127 expression and long-term antiviral memory in these patients. The reduced 3 expression of CD127 in viremic and HAART-treated patients suggests a shorter half-life of CD4+ 4 TCM cells in these groups. Further studies aimed at directly measuring TCM turnover will be 5 needed to confirm this point. Of note, the differences in CD127 expression did not extend to the 6 CD4+ TEM cell population. The three groups of patients showed a trend towards low CD127 The authors declare no competing financial interests. Brenchley, J. M., D. A. Price, T. W. Schacker, T. E. Asher, G. Silvestri, S. Rao, Z. 4 Kazzaz, E. Bornstein, O. Lambotte, D. Altmann, B. R. Blazar, B . Rodriguez, L. Teixeira- 
